DHS proposed the fee after a judge vacated a proclamation that slapped a six-figure charge on H-1B workers hired outside the U.S., finding it an illegal tax.
Clients are beginning to assume that if technology can forecast trends, flag anomalies, and surface insights instantly, then their accountant should be doing the same.
Phase 1 data from Generate Biomedicines’ ongoing chronic obstructive pulmonary disease study demonstrated “rapid and sustained reductions” across four disease biomarkers.
A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.
Limited opportunities and burnout are just two reasons biopharma professionals stop looking for work, with some pivoting away from the industry or turning to consulting. Two career coaches discuss why ending a job hunt is harmful and what to do instead.
Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 billion pie.
The Public Company Accounting Oversight Board has been restructuring several offices and plans to close its Office of the Investor Advocate in the next few weeks.
The Texas Society of CPAs is concerned about revenue agents requiring taxpayers to attend in-person interviews even when they have an tax pro representing them.